Sobi enters Research Collaboration with Affibody within the IL-1 field

Sobi has signed a research collaboration and option agreement with the Swedish
biotech company Affibody AB for the discovery and development of novel
treatments for inflammatory diseases where Interleukin-1 (IL-1) is implicated.

The research will be based on Affibody's proprietary technology platforms
Affibody® molecules and Albumod(TM) and includes up to five different targets
within the IL-1 field. All targets are key proteins involved in the regulation
of human immune and inflammatory processes. One project is a lead candidate for
the inhibition of IL-1 beta at the preclinical phase, and the others are in
discovery.

The agreement covers an initial two-year period during which Sobi has an option
to enter into a licensing agreement with worldwide exclusive rights to any or
all of the development projects. The agreement includes a payment by Sobi in the
amount of SEK 12 M, of which SEK 2.5 M at signing and the remaining part to be
paid over a 21-months period. In addition, the licensing agreement includes
potential future milestones and royalty after the two year period.

The IL-1 segment offers a good fit with Sobi's commercial focus with Kineret® in
the Inflammation therapeutic area, and with the Company's strategic biologics
development capabilities. The research will be carried out by both companies and
will be led by a joint steering committee. Affibody will have responsibility
through the discovery phase, and Sobi for clinical development. Each company
will bear their own costs. The agreement follows an earlier collaboration
between the companies regarding a biological candidate which has recently been
moved into IND-enabling studies.

"This agreement with Affibody deepens our collaboration by establishing a
strategic alliance in the area of inflammation," says CEO Geoffrey McDonough.
"We believe the Affibody® platform offers potentially unique therapeutic
advantages, and the efficient translation from discovery to biologics
development offered by our close association fits our innovation model very
well. This alliance allows us to take a positive step toward a more robust
presence in the inflammation field going forward."

"We are excited to extend our relationship with Sobi," says David Bejker, CEO of
Affibody. "IL-1 biology offers a number of opportunities to address unmet
medical needs and we believe that Sobi is in a good position to capitalize on
this segment based on their capabilities and existing presence in the field."



About IL-1
The Interleukin 1 family is a group of pro-inflammatory cytokines that play a
central role in the regulation of immune responses in the human body. The
cytokines are produced by different cells such as macrophages, monocytes and
fibroblasts, and via binding to cellular IL-1 receptors they participate in
acute and chronic inflammatory reactions. In addition, the IL-1 system is also
involved in several other biological functions, such as metabolic and
hematopoietic activities. Recently, members of the IL-1 family have emerged as
therapeutic targets for an expanding number of auto-inflammatory diseases where
inhibition of IL-1 activity may form the basis for novel treatments.



Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing
innovative therapies and services to improve the lives of rare disease patients.
The product portfolio is primarily focused on Inflammation and on Genetics and
Metabolism, and three late stage biological development projects within
hemophilia and neonatology. Sobi also has a portfolio of more than 40 products
which it commercializes on behalf of specialty and rare disease partners
companies.  In 2011, Sobi had revenues of SEK 1.9 billion and around 500
employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More
information is available at www.sobi.com.



About Affibody
Affibody is a Swedish biotech company focused on developing the next generation
of biopharmaceuticals based on its unique proprietary technology platforms:
Affibody® molecules and Albumod(TM). Affibody® molecules are a novel class of
antibody mimetics. Albumod(TM) is designed to enhance the efficacy of
biopharmaceuticals by extending their circulatory half-life. Affibody has
ongoing commercial relationships with several companies including Algeta,
Amylin, Sobi, GE Healthcare, and Thermo Fisher. The Company was founded in 1998
by researchers from the Royal Institute of Technology and the Karolinska
Institute and is based in Stockholm, Sweden. Major shareholders in the Company
include HealthCap and Investor Growth Capital. More information is available at
www.affibody.se.



For further information, please contact:
-Åsa Stenqvist, Head of Communications and IR at +46 8 697 21 88
-Stephen James, Head of Drug Design and Development at +46 8 697 28 24



The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on 10 July 2012 at 8.30 a.m. CET.